BMO Capital Starts Rigel Pharmaceuticals (RIGL) at Outperform, $4 PT
Tweet Send to a Friend
BMO Capital initiates coverage on Rigel Pharmaceuticals (NASDAQ: RIGL) with a Outperform rating and a price target of $4.00.Analyst Do ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
